Aravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities in the UK
November 14, 2024 04:00 ET
|
Aravax
MELBOURNE, Australia and OXFORD, United Kingdom, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe,...
Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
October 28, 2024 05:00 ET
|
Aravax
MELBOURNE, Australia, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely...
Aravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019 Annual Meeting
June 04, 2019 12:05 ET
|
Aravax
Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma MELBOURNE, Australia, June 04, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage...
Aravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019 Annual Meeting
May 28, 2019 15:15 ET
|
Aravax
Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy MELBOURNE, Australia, May 28, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage biotechnology company focused...
Aravax Presents Positive PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
February 24, 2019 15:15 ET
|
Aravax
Data show that PVX108, a peptide-based immunotherapy, has a highly favorable safety profile for the treatment of peanut allergy MELBOURNE, Australia, Feb. 24, 2019 (GLOBE NEWSWIRE) -- Aravax, a...
Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
February 13, 2019 09:08 ET
|
Aravax
Study designed to evaluate safety and tolerability of a novel peptide-based immunotherapy to treat peanut allergies MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage...